In a move that underscores their dedication to advancing patient-centric clinical research, Avance Clinical, a leading full-service Contract Research Organization (CRO), has teamed up with FindMeCure’s TrialHub, a state-of-the-art data intelligence platform, donating through their partnership a full patient scholarship to the EUPATI Patient Expert Programme.
Avance Clinical, known for their expertise in providing comprehensive clinical trial services, has long been committed to bringing research closer to patients, driving medical progress, and improving lives. By joining forces with TrialHub, Avance Clinical is taking a proactive step in supporting patient empowerment and education.
Avance Clinical’s Chief Scientific Officer, Dr Gabriel Kremmidiotis said, “Improving patient outcomes is a driving force at Avance Clinical. We are thrilled to join forces with TrialHub - a company that aligns with our vision of delivering high quality clinical trials, positively impacting healthcare outcomes globally. This collaboration enables us to expedite global delivery of patient-centred innovative biotechnology solutions.”
TrialHub's holistic, innovative approach to data and patient-centric philosophy mirror Avance Clinical's vision, making this partnership a natural fit. The EUPATI Patient Expert Programme, aimed at empowering patients with the knowledge and tools needed to engage meaningfully in medical research, resonates with both organizations' core values.
"TrialHub is delighted to collaborate with Avance Clinical," said Maya Zlatanova, CEO of TrialHub. "Our shared commitment to patient welfare and enhanced understanding of clinical research, as well as a vision that emphasises data-driven study feasibility drives this partnership. We believe that by supporting patient education and inclusion, we are contributing to more successful clinical trials and in turn, to the advancement of healthcare as a whole."
Through this collaboration, Avance Clinical and TrialHub aim to spotlight the importance of patient-centricity in the process of medicines research and development and encourage more organizations to take steps towards bridging the gap between medical research and patients.
About Avance Clinical
Avance Clinical is a full-service CRO for biotechs with a proven track-record for delivering clinical excellence in Australia, New Zealand, and North America. As the largest premium full-service CRO in Australia and North America, Avance Clinical specializes in delivering top-tier clinical trials that yield globally accepted data.
Award-winning CRO for Biotechs
Avance Clinical has been recognised for the fourth consecutive year by Frost & Sullivan in 2023, being awarded the Best Practices Customer Value Leadership for Biotech's award, for its continuous exceptional performance.
Pre-clinical through to Phase I and Beyond
Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance Clinical’s technology partners. www.avancecro.com
About TrialHub:
TrialHub is an NLP and AI-powered data intelligence platform dedicated to empowering clinical trial strategists with real-time insights on sites, competition, patients, and regulations. Thanks to thousands of validated data sources and the latest Generative AI capabilities we are able to answer any question thus ensuring knowledge across teams and data-driven decision-making towards more successful and patient-friendly clinical trials. Visit trialhub.com to learn more.